Workshops  Thursday 23rd February 2017


Registration Opens


Inaugural Varian Users’ Workshop
Integrated Clinical Solutions

0900 – 0920 Welcome

0920 – 1010 Keynote Presentation: Dr Bradley Prestidge

1010 – 1025 Morning Tea

1025 – 1045 Dr Bradley Prestidge

1045 – 1145 Workshop

1145 Conclusion

11:45 – 13:00

Lunch  –  Own arrangement


5th Oncentra Brachy User Group Meeting
From Nucletron to Elekta and beyond…

1300 – 1310 Welcome and Introduction to Elekta
Shaun Seery, Managing Director, Elekta ANZ

1310 – 1330 Treatment verification in brachytherapy – Should this be Standard of Care?
Professor Annette Haworth, Sydney University

1330 – 1400 Elekta’s Vision on Treatment Verification in Brachytherapy
Maarten Ter Mors, Director of Brachytherapy, Elekta

1400 – 1415 Update on TG 186 Model Based Dose Calculation Algorithms
Ryan Smith, Medical Physicist, William Buckland Radiotherapy Centre

1415 – 1430 Real time ultrasound-based high dose rate prostate brachytherapy: implementation and experience at St George Hospital
Dr  Andrej Bece, Brachytherapy Fellow, St George Hospital

1430 – 1445 Afternoon tea

1445 – 1500 Esteya Electronic Brachytherapy for Skin Cancer
Sandie Fisher, Physicist, Elekta ANZ

1500 – 1520 Radiobiology refresher: why is it important in brachytherapy?
Vanessa Panettieri, Medical Physicist

1520 – 1540 Elekta’s Radiobiological App Introducing Venezia™
Kirsten Bell, Brachytherapy Product Specialist, Elekta ANZ

1540 – 1600 “Can we move from 2D to 3D ultrasound based gynaecological brachytherapy?” A preliminary look at what is possible and what is needed.
Sylvia Van Dyk, Charge Brachytherapist, Peter MacCallum Cancer Centre

1600 – 1615 Looking Back at Brachytherapy in Australia
Peter Douglas, Director DTect Innovation

Closing Remarks
Shaun Seery


Day 1 concludes

17:30 – 19:30

Welcome Reception – SkyBar at Crown Metropol

Day 1  Friday 24th February 2017


Registration Opens


Welcome Address ABG 2017


Prof. Annette Haworth: Australasian Brachytherapy: Where are we going?


Parallel Session (GYN)

Parallel Session (Physics)

Image guided definitive radiotherapy of cervix cancer
Guest speaker: A/Prof Kailash Narayan

Physics Research and Development Session

Proffered Papers

Towards augmented reality: Intraoperative prostate modelling for biopsy and brachytherapy, Mohammad Ali Jan Ghasab, Monash University

BrachView: initial preclinical results for a real-time in-body HDR PBT source tracking system with simultaneous TRUS image fusion, Saree Alnaghy, Centre for Medical Radiation Physics, University of Wollongong

Characterisation of the Variseed dynamic volume calculation algorithm for Low Dose Rate prostate brachytherapy, Prabha Jones, Alfred Health – Gippsland Radiation Oncology

MaxiCalc: a real-time dose calculation engine for use in a HDR brachytherapy source tracking system, Max Hanlon, RMIT University

Feature finding for catheter localization in HDR prostate brachytherapy, Kyle Ewart, School of Applied Sciences, RMIT University

Implementation of a real-time prostate HDR brachytherapy system, Ryan Brown,St George Cancer Care Centre

Verification of skin doses during interstitial brachytherapy APBI, Dean Cutajar, Centre for Medical Radiation Physics, University of Wollongong


Proffered Papers

Clinical outcome of CT guided adaptive HDR brachytherapy combined with IMRT with chemotherapy in patients with locally advanced cervical cancer – the Royal Adelaide Hospital Experience, Kasri Abdul Rahim, Department of Radiation Oncology, Royal Adelaide Hospital

3T MR image-guided uterovaginal HDR brachytherapy modulated radiation therapy for cervix cancer – 6 year follow-up of disease outcomes and toxicity, Mark Stevens, Northern Sydney Cancer Centre, Royal North Shore Hospital


Morning Tea (Exhibition Area)


Keynote speaker – Prof. Mark Rivard: Research advances in brachytherapy physics: A perspective on technological advancements[new radionuclides and novel applicators]


Prof. Alexander Heriot, Colerectal Surgeon, Director Cancer Surgery, PMCC
IORT for recurrent rectal cancer

Parallel Session

Parallel Session


Proffered Papers

Interactive biologically-based inverse planning for focal LDR brachytherapy of prostate cancer, Jie Liu, Monash University

HDR brachytherapy in vivo source tracking using a 2D diode array: A Monte Carlo study, Joel Poder, Centre of Medical Radiation Physics, University of Wollongong

Accounting for previous radiotherapy treatments using deformable image registration: A case study in prostate brachytherapy, Johnson Yuen, St George Hospital, Cancer Care Centre

Patient Care Session

Urethral Strictures and other Complications from Radiation Therapy
Mr Alex Cato, Urologist

From Surviving to Thriving: Talking about Life after Prostate Cancer
Mr Danny Bryant, Clinical Psychologist

Dealing with Chronic Illness and Staying Positive day-to-day
Jason McIntyre, motorsport enthusiast and chronic pain survivor

ADT, Prostate Cancer and the Patient
Dr Jane Crowe, GP




Keynote speaker – Prof. Mark Rivard:Advances in brachytherapy dose calculation algorithms: State-of-the-art and developments underway

12:10 Proffered Papers

In-vivo dosimetry: Mehodology and results for HDR brachytherapy surface mould patients treated at the RAH since 2014, Paul Reich, Royal Adelaide Hospital

The introduction and validation of a model based dose calculation algorithm for brachytherapy in an Australian centre, Lynsey Hamlett, Townsville Hospital Cancer Centre

Do we need a minimum dwell time restriction in HDR brachytherapy treatments? Eeva Boman, Blood & Cancer Centre, Wellington Hospital





Lunch (Exhibition Area)


Gynaecological Brachytherapy

Guest speaker: Dr Graeme Dickie


Proffered Papers

Moulds and cylinders: Clinical and dosimetric analysis of an adjuvant image-guided intra-vaginal brachytherapy (IVBT) programme for endometrial cancer, Florence Ko, Northern Sydney Cancer Centre, Royal North Shore Hospital

Intracavitary vaginal brachytherapy using a custom balloon applicator, Dean Paterson, Wellington Blood and Cancer Centre

Interstitial HDR brachytherapy for an infant with prostate and bladder rhabdomyosarcoma, Emily Flower, Crown Princess Mary Cancer Centre, University of Sydney

Optimisation and dosimetric implication of treatment parameter changes in multi-lumen balloon breast brachytherapy, Claire Dempsey, Department of Radiation Oncology, University of Washington, Seattle WA, USA


Afternoon Tea  (Exhibition Area)


Keynote speaker – Assoc. Prof. Gerard Morton:HDR Monotherapy for prostate with extreme hypofractionation – (1 or 2 fractions).


Varian sponsored speaker – Dr Bradley Prestidge: RTOG 0232 – Phase III Study Comparing Combined External Beam Radiation And Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone For Selected Patients With Intermediate Risk Prostatic Carcinoma prostate brachytherapy clinical trial


ABG Annual General Meeting


Day 2 concludes


Conference Dinner Arrival Drinks : Zinc Federation Square


Conference Dinner


Conference Dinner Concludes

Day 2  Saturday 25th February 2017


Physics teaching lecture: Keynote speaker – Prof. Mark Rivard: Brachytherapy dose calculations and source strength determination


Registration Opens


Day 3 Welcome


Endometrial cancer and the PORTEC trials: the role of brachytherapy in outcome and quality of life

Keynote speaker: Claire Dempsey, University of Washington, Seattle USA


Proffered Papers

Round the bend – an unusual oesophageal brachytherapy case, Judith Martland, Northern Sydney Cancer Centre

Endobronchial brachytherapy as a palliative intervention: reviewing 20 years of experience in a Australian Centre, Matthew Knox, St George Hospital

Surface mould treatments at RAH, Lyndal Newmarch, Royal Adelaide Hospital

Electronic brachytherapy: commissioning and clinical experience of the Esteya system for superficial treatments, Bess Sutherland, Radiation Oncology Centres


Keynote speaker – Assoc. Prof. Gerard Morton:Management of high risk prostate cancer including ASCEND trial


Proffered Papers

Clinical demonstration of the value of in vivo Brachytherapy Image-Guided Verification (BIGV) in high dose rate prostate brachytherapy, Hayley Mack, Alfred Health Radiation Oncology

Re-implatation of iodine-125 seeds for suboptimal prostate brachytherapy post-implant dosimetry clinical and dosimetric outcomes, Andrej Bece, St George Hospital

Improved prostate cancer survival with the addition of high dose-rate brachytherapy to external beam radiation treatment and low toxicity with 12 year follow-up, Jeremy Millar, Alfred Health Radiation Oncology

Assessing prostate tumour cell density for focal brachytherapy using multiparametric MRI and machine learning techniques, Yu Sun, University of Melbourne


Morning Tea  (Exhibition Area)


Special Session LDR Prostate: Australasian Experience & Long Term Results: 
Results presented from:

  • New South Wales (St. George)
  • New Zealand (Wellington)
  • Queensland (combined groups)
  • South Australia (RAH)
  • Victoria (Alfred)
  • Western Australia (Sir Charles Gairdner)


Lunch (Exhibition Area)


Keynote speaker – Assoc. Prof. Gerard Morton: Salvage brachytherapy following external beam failures


Dr Bronwyn Matheson: Salvage brachytherapy literature review 
Dr Joseph Bucci: Salvage brachytherapy case studies


Proffered Papers

Salvage high dose rate brachytherapy for prostate cancer in South Australia, Hien Le, Royal Adelaide Hospital


Afternoon Tea  (Exhibition Area)


Keynote speaker – Assoc. Prof. Gerard Morton: Brachytherapy Education


Comprehensive quality management for clinical brachytherapy 

Keynote speaker: Prof Mark Rivard


Presentations & Wrap-up


Day 3 concludes

17:00 – 19:00

Post Session Drinks Promenade Hotel Tonic Bar

Poster Presentations:

HDR and LDR brachytherapy at the Royal Adelaide Hospital: A statistical review from 2004 to 2016, Wendy Phillips, Mr. John Lawson, Dr. Paul Reich, Royal Adelaide Hospital

APBI in patient with a defibrillator – a case study, Kristine Schreiber, St George Hospital Cancer Care Centre

Quantitative analysis of the Varian film – based position verification test using the DBSCAN clustering algorithm, Claire Dempsey, Department of Radiation Oncology, University of Washington, Seattle WA, USA


The program is correct as at 8 December but it is subject to change